Atlas Trials

Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV

Clinical trial NCT05070364 · UNKNOWN

Trial details

NCT number
NCT05070364
Sponsor
Eiger BioPharmaceuticals
Status
UNKNOWN
Phase
Phase 3
Study type
INTERVENTIONAL
Hepatitis Delta Virus
Start date
2021-12-21
Primary completion
2024-06-15
Enrollment
150

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.